Based on the frequency at which patients with severe COVID–19 suffer a cytokine storm, the use of cytokine–blocking drugs has been proposed in COVID–19 disease therapy, including anti–TNF antibodies [119], the IL–6 receptor (IL–6R) antagonist tocilizumab [120,121] and the IL–1R antagonist anakinra [122,123]. The gene discussed is TNF; the disease is COVID-19.